title: Orthovoltage radiation and weekly low dose of doxorubicin for the treatment of incompletely excised soft-tissue sarcomas in 39 dogs.
abstract: The efficacy and toxicity of orthovoltage radiation therapy and concurrent low doses of doxorubicin for the treatment of incompletely excised soft-tissue sarcomas in 39 dogs was investigated retrospectively. The 39 dogs had 40 soft-tissue sarcomas and received 51 Gy orthovoltage radiation in 17 daily 3 Gy fractions; they also received 10 mg/m(2) doxorubicin once a week administered intravenously one hour before the dose of radiation. The median follow-up time was 910 days. The tumours recurred locally in seven of the dogs, in five of them within the radiation field; the median time to their recurrence was 213 days (range 63 to 555 days). Six of the dogs developed a distant metastasis after a median time of 276 days (range eight to 826 days). The one-year and two- to four-year tumour control rates were 84 per cent and 81 per cent, respectively, and the one-, two- and three- to four-year survival rates were 85 per cent, 79 per cent and 72 per cent, respectively. Tumours with a mitotic rate of more than 9 per 10 high-power fields were significantly more likely to recur, and the dogs with such tumours survived for significantly shorter periods.
authors.affiliation: Harrington Oncology Program, Tufts University School of Veterinary Medicine, North Grafton, MA 01536, USA.
authors.forename: D
authors.initials: D
authors.lastname: Simon
authors.forename: D M
authors.initials: DM
authors.lastname: Ruslander
authors.forename: K M
authors.initials: KM
authors.lastname: Rassnick
authors.forename: C A
authors.initials: CA
authors.lastname: Wood
authors.forename: A E
authors.initials: AE
authors.lastname: Frimberger
authors.forename: S M
authors.initials: SM
authors.lastname: Cotter
authors.forename: N W
authors.initials: NW
authors.lastname: King
authors.forename: A S
authors.initials: AS
authors.lastname: Moore
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy / Q000662:veterinary; D018572:Disease-Free Survival; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage*; D005260:Female; D007262:Infusions, Intravenous / Q000662:veterinary; D008297:Male; D008404:Massachusetts; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy / Q000662:veterinary*; D011829:Radiation Dosage; D011996:Records / Q000662:veterinary; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy / Q000532:radiotherapy / Q000662:veterinary*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000662:veterinary*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin